Despite Aggressive Pricing, Illumina Expects Outsourced Sequencing to Remain Small Part of Business

An Illumina official said that sequencing services will remain a small part of its overall business and that the company does not expect the offering to have a negative impact on its instrument and consumables sales "in any reasonable horizon you could think of."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.